Sep 03, 2019 / 12:00PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Cidara Therapeutics' Rezafungin Partnership Agreement with Mundipharma Conference Call. (Operator Instructions) As a reminder, this conference call may be recorded.
I would now like to introduce your host for today's conference, Mr. Robert Uhl with Westwicke ICR. Sir, you may begin.
Robert H. Uhl - Westwicke Partners, LLC - MD
Thank you, Crystal. Good morning, everyone, and welcome to Cidara's conference call. Earlier this morning, we issued an important news release about the formation of a strategic development and commercialization partnership for rezafungin with Mundipharma. The press release with the details of the collaboration agreement can be found on the Cidara website. Joining me on the call from Cidara are Jeff Stein, President and Chief Executive Officer; and Jamie Levine, Chief Financial Officer.
Before I turn the call over to Jeff, I would like to note that all of the information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities
Cidara Therapeutics Inc and Mundipharma International Ltd Form Strategic Partnership to Develop and Commercialize Rezafungin - Conference Call Transcript
Sep 03, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers